Cepton Unveils Vista®-X90, Sets New Standard for High Performance, Automotive-Grade Lidar
22.9.2020 15:00:00 EEST | Business Wire | Press release
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced details of its groundbreaking automotive-grade lidar sensor – the Vista®-X90, priced at less than $1000 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005088/en/
With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, the compact, non-rotational Vista-X90 allows seamless vehicle integration. © 2020 Cepton Technologies.
The Vista-X90 is the newest addition to Cepton’s Vista-X automotive grade sensor family. It sets a new benchmark for high performance at low power in a compact form factor, and is ideally suited for advanced driver assistance systems (ADAS) and autonomous vehicles (AVs). Weighing less than 900 g, the Vista-X90 achieves up to 200 m range at 10% reflectivity with an outstanding angular resolution of 0.13° and state-of-the-art power consumption of <12W. The sensor supports frame rates of up to 40 Hz.
Optimized for ease of vehicle integration, the Vista-X90 has a licensable design architecture powered by Cepton’s patented Micro Motion Technology (MMT®) – a frictionless, mirrorless, rotation-free lidar architecture capable of high resolution and long range 3D imaging, while maximizing the sensor robustness and reliability to meet the stringent requirements of automotive applications.
Powered by Cepton’s next generation ASIC technology, the Vista-X90 is an ISO26262 ASIL-B sensor that supports AUTOSAR and over-the-air (OTA) functionality, with advanced capabilities for factory, extrinsic and dynamic calibration. With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, Vista-X90 is compact and embeddable. Its 90° x 25° field of view, combined with its directional, non-rotational design allows seamless vehicle integration - such as in the fascia, behind the windshield or on the roof.
Built with easily available and inexpensive components using a highly manufacturable, modular and scalable architecture, the Vista-X90 is ideally suited for high volume production to bring truly cost-effective lidar solutions to ADAS and AV markets. Cepton has licensed its technology to the world’s largest automotive headlamp Tier 1, Koito, who has non-exclusive rights to manufacture and sell Cepton’s lidar technology for an automotive application, using key modules supplied by Cepton.
“We are excited to disrupt the industry with the Vista-X90, which is the most cost-effective, high-performance lidar in the world for automotive applications,” said Dr. Jun Pei, Cepton’s CEO. “Automotive lidars have historically had either low performance at acceptable cost or claimed high performance while being too expensive for many OEM programs. The Vista-X90 fundamentally changes the game by bridging that divide and delivering the optimal mix of performance, power, reliability and cost. This is an integral part of our plan to make lidar available as an essential safety device in every consumer vehicle in the world.”
The Vista-X90 is targeted for production in 2022 and beyond, and samples can be made available upon request.
To learn more about the Vista-X90 and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming Automotive Lidar 2020 conference next week, between September 22 – 24, 2020. Please visit our virtual booth page and sign up to hear Cepton’s Senior Director of Business Development, Mitch Hourtienne, discuss the Vista lidars in his talk “Importance of Tier 1 Collaboration for an Automotive ADAS Production Program” on September 23 at 11:15 am EST.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as autonomous driving, ADAS, intelligent transportation systems (ITS), smart spaces and industrial robotics. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, UK, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005088/en/
Contact information
Faithy Li, Cepton Technologies, media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom